Ksilink is working on diseases with a high medical need. By applying break-through technologies and know-how we are combining medical needs with market expectations and technical feasability.
The complexity of patient based models is transforming entrenched work patterns between public research and industry. Access to patient derived, disease-relevant models and the most adequate competences for analyzing phenotypic screening results is becoming a competitive game changer. From an industry perspective, it is critical who will first access the relevant models – and further to that, who is able to best implement these models into the drug discovery process. Beside our in house expertise, Ksilink has access to a constantly growing network of leading clinicians and academics in France and Germany. Once the right partners are identified, Ksilink drives its collaborative drug discovery projects in a highly industrialized and standardized surrounding. Ksilink thus offers a critical advantage to its clients– with its established expertise it can generate validated patient based models within a short time.